The search for lupus biomarkers

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 4, 2009, Pages 507-523

  Liu, Chau Ching ^a,b   Ahearn, Joseph M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; diagnosis; disease activity; genetics; lupus; SLE

Indexed keywords

BIOLOGICAL MARKER; CD27 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4D; DOUBLE STRANDED DNA ANTIBODY; FC RECEPTOR; HLA ANTIGEN; INTERFERON; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 6; LA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; MANNOSE BINDING LECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOPONTIN; RO ANTIBODY; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANTIBODY DETECTION; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG RESEARCH; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PLASMA CELL; PRIORITY JOURNAL; RELIABILITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX;

EID: 67649811064     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.01.008     Document Type: Review

References (129)

1. Sherer Y., Gorstein A., Fritzler M.J., et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34 2 (2004) 501-537
2. Rahman A., and Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 358 9 (2008) 929-939
3. Cook H.T., and Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2 6 (2006) 330-337
4. Illei G.G., Tackey E., Lapteva L., et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 50 (2004) 1709-1720
5. Illei G.G., Tackey E., Lapteva L., et al. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 50 (2004) 2048-2065
6. Jonsen A., Gullstrand B., Guner N., et al. Genetically determined mannan-binding lectin deficiency is of minor importance in determining susceptibility to severe infections and vascular organ damage in systemic lupus erythematosus. Lupus 16 4 (2007) 245-253
7. Sestak A.L., Nath S.K., Sawalha A.H., et al. Current status of lupus genetics. Arthritis Res Ther 9 3 (2007) 210
8. Wakeland E.K., Liu K., Graham R.R., et al. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15 (2001) 397-408
9. Nath S.K., Kilpatrick J., and Harley J.B. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 16 6 (2004) 794-800
10. Hirose S., Jiang Y., Nishimura H., et al. Significance of MHC class II haplotypes and IgG Fc receptors in SLE. Springer Semin Immunopathol 28 2 (2006) 163-174
11. Croker J.A., and Kimberly R.P. Genetics of susceptibility and severity in systemic lupus erythematosus. [see comment]. Curr Opin Rheumatol 17 5 (2005) 529-537
12. Fairhurst A.M., Wandstrat A.E., and Wakeland E.K. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 92 (2006) 1-69
13. Rhodes B., and Vyse T.J. General aspects of the genetics of SLE. Autoimmunity 40 8 (2007) 550-559
14. Pickering M.C., Botto M., Taylor P.R., et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76 (2000) 227-324
15. Yang Y., Chung E.K., Zhou B., et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 7 (2004) 98-132
16. Law S.K.A., Dodds A.W., and Porter R.R. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 3 (1984) 1819-1823
17. Chung E.K., Yang Y., Rupert K.L., et al. Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins. Am J Hum Genet 71 4 (2002) 810-822
18. Yang Y., Chung E.K., Wu Y.L., et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80 6 (2007) 1037-1054
19. Fanciulli M., Norsworthy P.J., Petretto E., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 39 6 (2007) 721-723
20. Kyogoku C., Langefeld C.D., Ortmann W.A., et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75 3 (2004) 504-507
21. Lee Y.H., Rho Y.H., Choi S.J., et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology 46 1 (2007) 49-56
22. Wu H., Cantor R.M., Graham D.S., et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum 52 8 (2005) 2396-2402
23. Criswell L.A., Pfeiffer K.A., Lum R.F., et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76 4 (2005) 561-571
24. Chung S.A., and Criswell L.A. PTPN22: its role in SLE and autoimmunity. Autoimmunity 40 8 (2007) 582-590
25. Hooks J.J., Moutsopoulos H.M., Geis S.A., et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 1 (1979) 5-8
26. Kozyrev S.V., and Alarcon-Riquelme M.E. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 40 8 (2007) 591-601
27. Sigurdsson S., Nordmark G., Goring H.H., et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76 3 (2005) 528-537
28. Graham R.R., Kozyrev S.V., Baechler E.C., et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38 5 (2006) 550-555
29. Kelly J.A., Kelley J.M., Kaufman K.M., et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 9 3 (2008) 187-194
30. Kawasaki A., Kyogoku C., Ohashi J., et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms. Arthritis Rheum 58 3 (2008) 826-834
31. Graham R.R., Kyogoku C., Sigurdsson S., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104 16 (2007) 6758-6763
32. Sigurdsson S., Goring H.H., Kristjansdottir G., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 17 6 (2008) 872-881
33. Dieguez-Gonzalez R., Calaza M., Perez-Pampin E., et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum 58 5 (2008) 1264-1274
34. Korman B.D., Kastner D.L., Gregersen P.K., et al. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 8 5 (2008) 398-403
35. Remmers E.F., Plenge R.M., Lee A.T., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357 10 (2007) 977-986
36. Kobayashi S., Ikari K., Kaneko H., et al. Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum 58 7 (2008) 1940-1946
37. Palomino-Morales R.J., Rojas-Villarraga A., Gonzalez C.I., et al. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 9 4 (2008) 379-382
38. Martinez A., Varade J., Marquez A., et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 58 9 (2008) 2598-2602
39. Russell A.I., Cunninghame Graham D.S., Shepherd C., et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13 1 (2004) 137-147
40. Tsao B.P., Cantor R.M., Grossman J.M., et al. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 103 8 (1999) 1135-1140
41. International Consortium for Systemic Lupus Erythematosus G, Harley J.B., Alarcon-Riquelme M.E., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40 2 (2008) 204-210
42. Hom G., Graham R.R., Modrek B., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358 9 (2008) 900-909
43. Reveille J.D. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 13 5 (2004) 290-297
44. Manzi S., Navratil J.S., Ruffing M.J., et al. Measurement of erythrocyte C4d and complement receptor 1 in the diagnosis of systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3596-3604
45. Navratil J.S., Manzi S., Kao A.H., et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 54 2 (2006) 670-674
46. Liang M.H., Socher S.A., Larson M.G., et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32 (1989) 1107-1118
47. Bombardier C., Gladman D.D., Urowitz M.B., et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
48. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86 7 (1993) 447-458
49. Liu C.-C., Ahearn J.M., and Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep 6 (2004) 85-88
50. Isenberg D.A., Manson J.J., Ehrenstein M.R., et al. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. Rheumatology 46 7 (2007) 1052-1056
51. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2 9 (2001) 764-766
52. Odendahl M., Jocobi A., Hansen A., et al. Disturbed peripheral B lymphocyte homeostasis in systmic lupus erythematosus. J Immunol 165 (2000) 5970-5979
53. Arce E., Jackson D.G., Gill M.A., et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 167 4 (2001) 2361-2369
54. Jacobi A.M., Odendahl M., Reiter K., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48 5 (2003) 1332-1342
55. Liu C.C., Manzi S., Kao A.H., et al. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus eryhematosus. Arthritis Rheum 52 (2005) 3087-3099
56. Baechler E.C., Batliwalla F.M., Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100 (2003) 2610-2615
57. Crow M.K., and Kirou K.A. Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16 (2004) 541-547
58. Ronnblom L., Eloranta M.L., and Alm G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54 2 (2006) 408-420
59. Pascual V., Farkas L., and Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Rheumatol 18 6 (2006) 676-682
60. Han G.M., Chen S.L., Shen N., et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 4 3 (2003) 177-186
61. Bennett L., Palucka K.A., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197 (2003) 711-723
62. Kirou K.A., Lee C., George S., et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52 5 (2005) 1491-1503
63. Bauer J.W., Baechler E.C., Petri M., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3 12 (2006) e491
64. Feng X., Wu H., Grossman J.M., et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54 9 (2006) 2951-2962
65. Vila L.M., Molina M.J., Mayor A.M., et al. Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 26 5 (2007) 718-722
66. Nikpour M., Dempsey A.A., Urowitz M.B., et al. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 67 8 (2008) 1069-1075
67. Kirou K.A., Lee C., George S., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50 12 (2004) 3958-3967
68. Landolt-Marticorena C., Bonventi G., Lubovich A., et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis (2008) (online publication; Sept. 4)
69. Petri M., Tesfasyone H., Singh S., et al. The systemic lupus erythematosus interferon signature is associated with current activity and is also predictive of hematologic and mucocutaneous disease activity at the next visit. Arthritis Rheum 52 9 Suppl (2005) S464
70. Baechler E.C., Batliwalla F., Ortmann W.A., et al. Gene signatures in peripheral blood predict future disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52 9 Suppl. (2005) S700
71. Kariuki S.N., Crow M.K., and Niewold T.B. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 58 9 (2008) 2813-2823
72. Niewold T.B., Kelly J.A., Flesch M.H., et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58 8 (2008) 2481-2487
73. Ronnblom L., and Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17 5 (2008) 394-399
74. Yan B., Ye S., Chen G., et al. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 58 3 (2008) 801-812
75. Lee P.Y., Li Y., Richards H.B., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56 11 (2007) 3759-3769
76. Denny M.F., Thacker S., Mehta H., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110 8 (2007) 2907-2915
77. Moore P.A., Belvedere O., Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285 5425 (1999) 260-263
78. Nardelli B., Belvedere O., Roschke V., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97 1 (2001) 198-204
79. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 6781 (2000) 995-999
80. Mackay F., Woodcock S.A., Lawton P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 11 (1999) 1697-1710
81. Zhang J., Roschke V., Baker K.P., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 1 (2001) 6-10
82. Cheema G.S., Roschke V., Hilbert D.M., et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 6 (2001) 1313-1319
83. Pers J.O., Daridon C., Devauchelle V., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 (2005) 34-39
84. Becker-Merok A., Nikolaisen C., and Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15 9 (2006) 570-576
85. Harigai M., Kawamoto M., Hara M., et al. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Rheumatol 181 3 (2008) 2211-2219
86. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 12 (2003) 3475-3486
87. Petri M., Stohl W., Chatham W., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58 8 (2008) 2453-2459
88. Stuart R.A., Littlewood A.J., Maddison P.J., et al. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 13 1 (1995) 17-22
89. Houssiau F.A., Lefebvre C., Vanden Berghe M., et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4 5 (1995) 393-395
90. Lard L.R., Roep B.O., Verburgh C.A., et al. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11 3 (2002) 181-185
91. Davas E.M., Tsirogianni A., Kappou I., et al. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18 1 (1999) 17-22
92. Spronk P.E., Bootsma H., Huitema M.G., et al. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 97 3 (1994) 439-444
93. Sjowall C., Bengtsson A.A., Sturfeldt G., et al. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6 (2004) R87-R94
94. Cameron J.S. Lupus nephritis. J Am Soc Nephrol 10 2 (1999) 413-424
95. Simon J.A., Cabiedes J., Ortiz E., et al. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 43 2 (2004) 220-224
96. Gutierrez-Adrianzen O.A., Koutouzov S., Mota R.M., et al. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 33 8 (2006) 1538-1544
97. Seelen M.A., Trouw L.A., and Daha M.R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 12 (2003) 619-624
98. Potlukova E., and Kralikova P. Complement component c1q and anti-c1q antibodies in theory and in clinical practice. Scand J Immunol 67 5 (2008) 423-430
99. Mohan C., Adams S., Stanik V., et al. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177 5 (1993) 1367-1381
100. Chabre H., Amoura Z., Piette J.C., et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 38 10 (1995) 1485-1491
101. Ravirajan C.T., Rowse L., MacGowan J.R., et al. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology 40 12 (2001) 1405-1412
102. Cairns A.P., McMillan S.A., Crockard A.D., et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 62 3 (2003) 272-273
103. Min D.J., Kim S.J., Park S.H., et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 20 1 (2002) 13-18
104. Bigler C., Lopez-Trascasa M., Potlukova E., et al. Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis 51 4 (2008) 624-629
105. Horvath L., Czirjak L., Fekete B., et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 19 6 (2001) 667-672
106. Moroni G., Trendelenburg M., Papa N.D., et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37 (2001) 490-498
107. Marto N., Bertolaccini M.L., Calabuig E., et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64 3 (2005) 444-448
108. Trendelenburg M., Marfurt J., Gerber I., et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 42 (1999) 187-188
109. Trendelenburg M., Lopez-Trascasa M., Potlukova E., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 21 11 (2006) 3115-3121
110. Hanly J.G. New insights into central nervous system lupus: a clinical perspective. Curr Rheumatol Rep 9 2 (2007) 116-124
111. Bluestein H.G. Antibodies to brain. In: Wallace D.J., and Hahn B. (Eds). Dubois' lupus erythematosus. 5th edn. (1997), Williams & Wilkins, Baltimore 517-522
112. DeGiorgio L.A., Konstantinov K.N., Lee S.C., et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 7 11 (2001) 1189-1193
113. Kowal C., DeGiorgio L.A., Nakaoka T., et al. Cognition and immunity; antibody impairs memory. Immunity 21 2 (2004) 179-188
114. Huerta P.T., Kowal C., DeGiorgio L.A., et al. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 103 3 (2006) 678-683
115. Kowal C., Degiorgio L.A., Lee J.Y., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103 52 (2006) 19854-19859
116. Husebye E.S., Sthoeger Z.M., Dayan M., et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 64 8 (2005) 1210-1213
117. Arinuma Y., Yanagida T., and Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 58 4 (2008) 1130-1135
118. Lapteva L., Nowak M., Yarboro C.H., et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54 8 (2006) 2505-2514
119. Harrison M.J., Ravdin L.D., and Lockshin M.D. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 54 8 (2006) 2515-2522
120. Hanly J.G., Robichaud J., and Fisk J.D. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 33 8 (2006) 1553-1558
121. Omdal R., Brokstad K., Waterloo K., et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 12 5 (2005) 392-398
122. Yoshio T., Onda K., Nara H., et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 54 2 (2006) 675-678
123. Hood L., and Perlmutter R.M. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 22 10 (2004) 1215-1217
124. Kyttaris V.C., Krishnan S., and Tsokos G.C. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity 39 8 (2006) 705-709
125. Petricoin E.F., Zoon K.C., Kohn E.C., et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1 9 (2002) 683-695
126. Utz P.J. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. Lupus 13 5 (2004) 304-311
127. Forabosco P., Gorman J.D., Cleveland C., et al. Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus. Genes Immun 7 7 (2006) 609-614
128. Li Q.Z., Zhou J., Wandstrat A.E., et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 147 1 (2007) 60-70
129. Chaussabel D., Quinn C., Shen J., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29 1 (2008) 150-164